• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinical Investigator Warned for ClinicalTrials.gov Noncompliance

Clinical Investigator Warned for ClinicalTrials.gov Noncompliance

September 13, 2021

A Los Angeles doctor is the first individual investigator to receive an FDA warning letter for failing to report trial results to ClinicalTrials.gov, a violation that could result in thousands of dollars in fines, the letter said.

In an Aug. 31 letter, the agency warned Andrey Petrikovets that he had 30 days to submit to the ClinicalTrials.gov registry results of a phase 4 postoperative pain-relief trial he conducted at the University Hospitals Cleveland Medical Center. The trial concluded in June 2018 and the agency first notified Petrikovets of his noncompliance in a July 20, 2021, letter.

Petrikovets submitted the results to ClinicalTrials.gov one day after receiving the warning letter, sidestepping a potential fine of at least $10,000 for every day he was in noncompliance. According to the registry’s website, the information is currently undergoing quality control review before being posted.

The Petrikovets letter is the third such warning the FDA has given for noncompliance with ClinicalTrials.gov requirements. Previously, the agency cited two trial sponsors — Acceleron Pharma and Accuitis — for the same violation (CenterWatch Weekly, Aug. 23).

Read the warning letter at https://bit.ly/3C3n8Uz.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing